Protocol for Outpatient Screening and Initiation of Continuous Subcutaneous Insulin Infusion Therapy: Impact on Cost and Quality

The Diabetes Educator

Volumn 28, Issue 4, 2002, Pages 599-607

  Sanfield, Jeffrey A ^a   Hegstad, Marcia ^b   Hanna, Raouf S ^b  

^a EASTERN MICHIGAN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

AMBULATORY CARE; ARTICLE; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; FOLLOW UP; HUMAN; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; MASS SCREENING; METABOLISM; METHODOLOGY; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; STANDARD;

ACTIVITIES OF DAILY LIVING; AMBULATORY CARE; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN; LIFE STYLE; MASS SCREENING; NURSING ASSESSMENT; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0036633637     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572170202800414     Document Type: Article

References (23)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. American Diabetes Association. Routine management: objectives. In: Kelley DB, ed. Medical Management of Type 1 Diabetes. 3rd ed. Alexandria, Va: American Diabetes Association; 1998:24-47.
3. Bell DSH, Ackerson C, Cutter G, Clements RS Jr. Factors associated with discontinuation of continuous subcutaneous insulin infusion. Am J Med Sci. 1988;295:23-28.
4. Floyd JC, Cornell RG, Jacober SJ, et al. A prospective study identifying risk factors for discontinuance of insulin pump therapy. Diabetes Care. 1993; 16:1470-1478.
5. Jornsay DL, Duckles AE, Hankinson JP. Psychological considerations for patient selection and adjustment to insulin pump therapy. Diabetes Educ. 1988;14:291-296.
6. Leichter SB, Schreiner ME, Reynolds LR, Bolick T. Long-term follow-up of diabetic patients using insulin infusion pumps: considerations for future clinical application. Arch Intern Med. 1985;145:1409-1412.
7. Wolf FM, Jacober SJ, Wolf LL, Cornell RG, Floyd JC. Quality of life activities associated with adherence to insulin infusion pump therapy in the treatment of insulin-dependent diabetes mellitus. J Clin Epidemiol. 1989;42:1129-1136.
8. Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of continuous subcutaneous insulin infusion therapy. Diabetes Care. 1988;11:46-51.
9. Mecklenburg RS. Acute complications associated with the use of insulin infusion pumps. Diabetes Educ. 1989; 15:40-43.
10. Diabetes Control and Complications Research Group. DCCT Manual of Operations. Springfield, Va: 1993.
11. Herman WH, Dasbach EJ, Songer TJ, Thompson DE, Crofford OB. Assessing the impact of intensive insulin therapy on the health care system. Diabetes Rev. 1994;2:384-388.
12. Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1468-1478.
13. Campbell DT, Stanley JC. Experimental and Quasi-Experimental Designs for Research. Chicago: Rand McNally College Publishing Co; 1963.
14. American Diabetes Association. Continuous subcutaneous insulin infusion (position statement). Diabetes Care. 2001;24(suppl 1):S98-S98.
15. Ware JE Jr., Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute - New England Medical Center; 1993.
16. Annotated Bibliography for the SF-36 Health Survey. Boston: The Health Institute - New England Medical Center; 1996.
17. Stewart AL, Ware JE. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.
18. Farkas-Hirsch R, Hirsch IB. Continuous subcutaneous insulin infusion: a review of the past and its implementation for the future. Diabetes Spectrum. 1994;7:80-84, 136-138.
19. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996; 19:324-327.
20. Wredling R, Hannerz L, Johansson UB. Variability of blood glucose levels in patients treated with continuous subcutaneous insulin infusion: a pilot study. Pract Diabetes Int. 1997; 14:5-8.
21. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46:440-443.
22. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R; on behalf of the German Humalog-CSII Study Group. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care. 1999;22:784-788.
23. Hirsch B, The evolution of diabetes technology: how are we doing? Clin Diabetes. 2000; 18:49-50.